Importer of Controlled Substances; Notice of Application, 3545-3546 [E6-718]

Download as PDF 3545 Federal Register / Vol. 71, No. 14 / Monday, January 23, 2006 / Notices Alexandria, Virginia 22301; and must be filed no later than (60 days from publication). DEPARTMENT OF JUSTICE Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–720 Filed 1–20–06; 8:45 am] Importer of Controlled Substances; Notice of Application BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application erjones on PROD1PC61 with NOTICES Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 31, 2005, Clariant LSM (Missouri), Inc., 2460 W. Bennett Street (or P.O. Box 1246, Zip: 65801), Springfield, Missouri 65807– 1229, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Phenylacetone (8501), and Methadone Intermediate (9254), a basic class of controlled substances listed in Schedule II. The company plans to manufacture in bulk, for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 24, 2006. Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–719 Filed 1–20–06; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 13:01 Jan 20, 2006 Jkt 208001 Drug Enforcement Administration Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on August 10, 2005, Clinical Trial Services (US), 2661 Audubon Road, Audubon, Pennsylvania 19403, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801) and Oxycodone (9143), basic classes of controlled substance listed in Schedule II. The company plans to import small quantities of the listed controlled substance in dosage form to conduct clinical trials. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than February 22, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–717 Filed 1–20–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on July 27, 2005, Cody Laboratories Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414–9321, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in Schedule II: Drug Raw Opium (9600) ....................... Poppy Straw (9650) ...................... Concentrate of Poppy Straw (9670). Schedule II II II The company plans to import narcotic raw materials for manufacturing and further distribution to its customers. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, E:\FR\FM\23JAN1.SGM 23JAN1 3546 Federal Register / Vol. 71, No. 14 / Monday, January 23, 2006 / Notices Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than February 22, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 24, 2006. Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–716 Filed 1–20–06; 8:45 am] BILLING CODE 4410–09–P Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–718 Filed 1–20–06; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P By Notice dated October 18, 2005, and published in the Federal Register on August 19, 2005, (70 FR 48780), Sigma Aldrich Research Biochemicals, Inc., 1– 3 Strathmore Road, Natick, Massachusetts 01760, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of NBenzylpiperazine (7493), a basic class of controlled substance listed in Schedules I. The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. § 823(a) and determined that the registration of Sigma Aldrich Research, Biochemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research, Biochemicals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 12, 2005, National Center for Natural Products Research—NIDA MProject, University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38577, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I: Drug Schedule erjones on PROD1PC61 with NOTICES Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... I I The company plans to cultivate marihuana for the National Institute of Drug Abuse for research approved by the Department of Health and Human Services. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance VerDate Aug<31>2005 13:01 Jan 20, 2006 Jkt 208001 PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: January 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–715 Filed 1–20–06; 8:45 am] BILLING CODE 4410–09–P NATIONAL SCIENCE FOUNDATION National Science Board; Workshop on Hurricane Science and Engineering; Toward A National Agenda for Hurricane Science and Engineering: Perspectives From Federal Agencies Date and Time: January 24, 2005, 8 a.m.–5:15 p.m. (ET). Place: National Science Foundation, 4201 Wilson Boulevard, Room 1235, Arlington, VA 22230. Public Meeting Attendance: All visitors must report to the NSF’s visitor’s desk at the 9th and N. Stuart Streets entrance to receive a visitor’s badge. Contact Information: Please refer to the National Science Board Web site (https://www.nsf.gov/nsb) for updated Agenda. NSB Office: (703) 292–7000. Status: This Workshop will be open to the public. Provisional Workshop Agenda 8–8:05 a.m. Welcoming Remarks. 8:05–8:20 a.m Motivation, Purpose and Goals. 8:20–8:30 a.m. Process and Logistics for NSB Workshops. 8:30–9:30 a.m. Panel Session I: Physical, Biological and Ecological Sciences. 9:30–10 a.m. Roundtable Discussion. 10–10:15 a.m. Break. 10:15–11:15 a.m. Panel Session II: Social, Behavioral, and Economic Sciences. 11:15–11:45 a.m. Roundtable Discussion. 1–2 p.m. Panel Session III: Engineering and Infrastructure. 2–2:30 p.m. Roundtable Discussion. 2:30–4 p.m. Break-Out Groups (3 concurrent sessions). 4–5 p.m. Break-Out Group Reports and Discussion. 5–5:15 p.m. Summary and Next Steps. 5:15 p.m. Adjourn. Michael P. Crosby, Executive Officer and NSB Office Director. [FR Doc. E6–711 Filed 1–20–06; 8:45 am] BILLING CODE 7555–01–P E:\FR\FM\23JAN1.SGM 23JAN1

Agencies

[Federal Register Volume 71, Number 14 (Monday, January 23, 2006)]
[Notices]
[Pages 3545-3546]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-718]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on July 27, 2005, Cody Laboratories Inc., 601 Yellowstone Avenue, 
Cody, Wyoming 82414-9321, made application to the Drug Enforcement 
Administration (DEA) to be registered as an importer of the basic 
classes of controlled substances listed in Schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Raw Opium (9600)............................  II
Poppy Straw (9650)..........................  II
Concentrate of Poppy Straw (9670)...........  II
------------------------------------------------------------------------

    The company plans to import narcotic raw materials for 
manufacturing and further distribution to its customers.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic classes of controlled substances may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration,

[[Page 3546]]

Washington, DC 20537, Attention: DEA Federal Register Representative, 
Liaison and Policy Section (ODL); or any being sent via express mail 
should be sent to DEA Headquarters, Attention: DEA Federal Register 
Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 
22301; and must be filed no later than February 22, 2006.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substance listed 
in Schedule I or II are, and will continue to be required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

    Dated: January 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-718 Filed 1-20-06; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.